

9 September 2025

**Aptamer Group plc**

("Aptamer", the "Company" or the "Group")

**Notification of dealings by a director/PDMR**

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announces that Dr Adam Hargreaves, Non-Executive Chairman, on 8 September 2025 purchased 5,000,000 ordinary shares of £0.001 each ("Ordinary Shares") in the Company at a price of 1 pence per Ordinary Share, through Pathcelerate Limited.

Following this transaction, Dr Adam Hargreaves total beneficial interest in the Company is 175,379,305 Ordinary Shares, representing approximately 6.50% of the Company's issued share capital.

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the purchase of ordinary shares by directors and other PDMRs in the Company.

**NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Dr Adam Hargreaves (Pathcelerate Limited)
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Aptamer Group plc
b)	LEI	213800Y4XGH3WJNBE686
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.001 each
	Identification code	GB00BNRRP542
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Price 1p Volume 5,000,000
d)	Aggregated information	
	- Aggregated volume	5,000,000
	- Price	1p
e)	Date of the transaction	8 September 2025
f)	Place of the transaction	London Stock Exchange

- Ends -

For further information, please contact:

<b>Aptamer Group plc</b>	+44 (0) 1904 217 404
Dr Arron Tolley, Chief Executive Officer	
<b>SPARK Advisory Partners Limited - Nominated Adviser</b>	+44 (0) 20 3368 3550
Andrew Emmott / Jade Bayat	
<b>Turner Pope Investments (TPI) Limited - Broker</b>	+44 (0) 20 3657 0050
James Pope / Andrew Thacker	
<b>Northstar Communications Limited - Investor Relations</b>	+44 (0) 113 730 3896
Sarah Hollins	

#### About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimiser® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US 210 billionmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimiser® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to <https://aptamergroup.com/investors/investor-news-email-alerts/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHLP MRTMTAMBJA